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42.7% were female. A 16 item instrument was developed and
reﬁned using cognitive interviews (n = 26). The new instrument is
currently being evaluated for validity and sensitivity. CONCLU-
SIONS: Patient self-management of type 2 diabetes is a crucial
element of successful outcomes in both research studies and
clinical practice settings. The Diabetes Self-Management Proﬁle
will be useful for measuring the impact of different treatment
modalities on patients’ ability to manage the multiple aspects of
their Type 2 diabetes.
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OBJECTIVES: To validate the Human Growth Hormone Pref-
erence and Satisfaction Questionnaire (HGH-PSQ), a new instru-
ment for assessing preference for and satisfaction with HGH
treatment modalities. METHODS: Following IRB approval, the
initial instrument was pilot tested at 4 clinical sites specializing in
pediatric endocrinology. Clinicians, patients, and parents partici-
pated in assessing the properties, overall functionality, and com-
prehension of the instrument. Eligible patients completing the
instrument were children and adolescents 10–18 years old, and
were either new or established users of HGH. Face validity,
statistical validity, internal reliability, domain intercorrelations,
and test-retest reliability were assessed for each domain, as well
as for the entire instrument. RESULTS: Forty-nine patients and
their parents were administered the instrument, with 48 complet-
ing the retest. Following structured feedback and statistical
analysis, the ﬁnal instrument was reduced to 27 items in the
patient version and 30 items in the parent version, covering 5
domains of affect, non-interference, ease of administration/
preparation, pain, and overall satisfaction. Structured develop-
ment of the instrument with input from clinicians,
psychometricians, patients and their families ensured maximum
face validity. Variability and distribution in scores supported
statistical validity of the instrument. Strong internal reliability
was indicated, with Cronbach’s alpha of 0.85 and 0.89 for the
patient and parent versions, respectively. Intercorrelation coefﬁ-
cients for each domain with the overall instrument score demon-
strated convergent and discriminant validity. The instrument also
had good overall test-retest reliability, with correlations of 0.80
for patients and 0.73 for parents, with moderate to good coefﬁ-
cients for the individual domains. CONCLUSIONS: The HGH-
PSQ shows good psychometric properties and appears to be a
valid and reliable instrument to evaluate overall treatment satis-
faction with and patient preference for HGH delivery devices.
Future studies using larger samples of new users with HGH are
warranted to examine the sensitivity of the instrument to detect
differences among treatments.
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OBJECTIVES: Insulin is a potent drug available to manage dia-
betes and avoid serious complications and disease progression.
Unfortunately, psychological insulin resistance (PIR) is not
uncommon and negatively inﬂuences both initiation and com-
pliance with insulin treatment. Thus, understanding etiologies
of PIR is critical to ensure optimal diabetes management.
METHODS: Systematic literature review of peer reviewed jour-
nals using MEDLINE database including all articles (English)
from 1985–2007. The keywords and phrases used for the
search included psychological insulin resistance, type 1/2 dia-
betes, resistance to insulin therapy, insulin side effects/
complications, reluctance to treat, treatment refusal, barriers to
compliance, switching, racial/ethnic/cultural/gender issues/
barriers initiating insulin, patient reluctance, psychological
adjustment, needle/injection anxiety/phobia/fear, psycho-social
aspects, patient perceptions, acceptance/adherence and patient
preference. A total of 106 articles were reviewed. RESULTS:
Multiple etiologies of PIR were identiﬁed including patients’
beliefs and knowledge about diabetes/insulin, negative self per-
ceptions and attitudinal barriers, fear of side effects, complica-
tions from insulin use, social stigma and lifestyle adaptations
required by insulin use. Gender, socio-economics and culture
may modify this impact. Additionally, individual or physician
beliefs that one cannot comply with treatment or cope with
repeated blood tests, fear of hypoglycemia or weight gain and
physicians’ previous experience with insulin may also contrib-
ute to PIR. These etiological inﬂuences, both independently
and in combination, constitute patients’ PIR and may results
in compromised glucose control. CONCLUSIONS: PIR is
complex and multifaceted and plays an important, often
ignored role in diabetes management. This presentation will
review the full scope of PIR etiologies and discuss treatment
implications. Assisting health care professionals to better under-
standing PIR and tailor insulin treatment modalities accord-
ingly (e.g., with modern insulin analogues associated with less
weight gain and less hypoglycemia and/or insulin pen devices),
may greatly reduce patients’ PIR associated with using human-
insulin in vial and syringe.
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OBJECTIVES: Approximately 90% of the diabetes population
has type 2 diabetes, which has been predicted to become the
epidemic of the 21st century. Treatment satisfaction is not only an
important patient-reported outcome (PRO) but also a signiﬁcant
predictor of medication adherence, with implications for the
prevention of long-term complications, e.g. retinopathy, neuropa-
thy, nephropathy. The FDAhasmade recommendations regarding
the development and use of PRO measures. Our aim was to
identify treatment satisfaction questionnaires for use in non-
insulin-treated type 2 diabetes and scrutinize their development
history and psychometric properties. METHODS: We used a
PICO (population, intervention, competitor and outcome) strat-
egy to search Scopus from 2000 to present for relevant articles.
Key search terms included “type 2 diabet*” and “satisfact*”.
Following screening, speciﬁc searches for instrument names and
citation searches were then conducted.RESULTS:A total of 2154
abstracts were screened. Four treatment satisfaction instruments
were identiﬁed as designed for use in non-insulin-treated type 2
diabetes: the Diabetes Treatment Satisfaction Questionnaire
(DTSQ), the Diabetes Medication Satisfaction (Diab-MedSat)
questionnaire, the Diabetes Tablet Treatment Questionnaire
(DTTQ) and the Satisfaction with Oral Anti-Diabetic Agent Scale
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(SOADAS). Eleven papers were included in a critical review of the
instruments. Development histories and psychometric properties
were largely adequate though each instrument was lacking in
some aspect. Each instrument has its individual merits; the 8-item
DTSQ, 7-itemDTTQ and 6-item SOADAS offer brevity, while the
21-item Diab-MedSat offers a more detailed approach. The
DTTQ and SOADAS focus speciﬁcally on tablet treatment, while
the DTSQ and Diab-MedSat enable within-groups comparisons
when changing treatment from tablets to insulin. CONCLU-
SIONS: The DTSQ, the Diab-MedSat, the DTTQ and the
SOADAS have acceptable development histories and psychomet-
ric properties, though evidence for both could be strengthened in
certain areas to fulﬁl the FDA’s requirements. Given the differing
focus/length of each instrument, selection will also depend on
study objectives.
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BACKGROUND: Diabetes is a common chronic condition
affecting several millions of people in the United States. Insulin
supplementation is essential for controlling diabetes. However,
not all patients are receptive to taking injectable insulin and are
therefore more likely to be noncompliant with therapy. Inhaled
insulin is as efﬁcacious as subcutaneous insulin, but patients’
willingness to pay for inhaled insulin and the factors that affect
their willingness to pay (WTP) are unknown. OBJECTIVES: To
determine (1) the relationship of patient satisfaction with current
insulin therapy and demographic factors on WTP for inhaled
insulin, and (2) predictors of patients’ WTP for inhaled insulin.
METHODS: Exploratory cross-sectional study design using a
random sample of diabetic patients from a national database.
Data were collected using a mailed survey that focused on a
patient satisfaction, willingness to pay, and general patient infor-
mation. Patient satisfaction was measured the Patient Satisfac-
tion with Insulin Therapy (PSIT) scale. Data were analyzed using
SPSS v.15.0 with an a priori alpha of 0.05. Descriptive statistics,
Point-biserial and Pearson correlations, Chi-Square analyses,
and Linear and Logistic regression modeling were conducted.
RESULTS: One hundred twenty-eight patients responded.
Annual household income, type of diabetes, patient satisfaction
with current insulin therapy, gender, number of insulin injections
per day, and current cost of insulin therapy were found to have
a signiﬁcant relationship with WTP. Annual household income
and patient satisfaction predict patients’ WTP, X2 (9,
N = 114) = 27.45, p = 0.001.While, current cost of insulin
therapy and annual income were found to be signiﬁcant predic-
tors of how much patients were willing to pay for inhaled insulin,
R2 = 0.242, p < 0.05. CONCLUSIONS: Patients with higher
annual incomes and those who are dissatisﬁed with their current
insulin therapy are willing to pay for inhaled insulin. Also,
patients with higher annual income and higher current cost of
insulin therapy are willing to pay more for inhaled insulin.
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OBJECTIVES: To compare treatment satisfaction (TS) associ-
ated with insulin administration in type 2 diabetes subjects
treated with either insulin glargine based regimens or Neutral
Protamine Hagedorn (NPH) insulin based regimens for at
least 6 months. METHODS: As part of a comparative, non-
interventional, multi-centre, cross-sectional study in a primary
care setting in Germany, patients with insulin-dependent type 2
diabetes completed the Insulin Treatment Experience Question-
naire (ITEQ), a new condition-speciﬁc instrument assessing TS,
and the Diabetes Treatment Satisfaction Questionnaire (DTSQs).
The ITEQ contained 28 items among seven subscales (leisure
activities, psychological barriers, handling, diabetes control,
dependence, weight control, sleep); forming an ITEQ total score
transformed as 0 to 100, with 100 indicates high treatment
satisfaction. To examine differences between the two treatment
groups Mann-Whitney U tests were used. Multivariate linear
regression models were performed to determine differences
between treatment groups, controlling for sociodemographic and
diabetes-related characteristics, respectively. RESULTS: Overall,
1858 individuals were enrolled in the study, and TS analyses were
conducted with data from the 1,602 per protocol patients (982
insulin glargine and 620 NPH insulin). Demographic data of
patients receiving either insulin glargine or NPH insulin were
similar. DTSQs satisfaction score, ITEQ subscales and ITEQ
total score differed between therapy regimens and were signiﬁ-
cantly higher in the insulin glargine group (DTSQs: 29.9  5.5
vs. 29.2  5.7, p = 0.01; ITEQ total score: 71.5  13.1 vs.
67.6  13.9, p < 0.001). Results of the regression models indi-
cate that differences between the groups were stable after adjust-
ment. CONCLUSIONS: Our results indicate that insulin glargine
was associated with signiﬁcant higher treatment satisfaction
compared to NPH insulin among patients with type 2 diabetes.
The results suggest that the use of insulin glargine provide an
additional treatment beneﬁt for type 2 patients with insulin
dependent diabetes mellitus.
DIABETES/ENDOCRINE DISORDERS—Health Care Use
& Policy Studies
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OBJECTIVES: 1) To compare means of calories burnt by exer-
cise, compliance, eating behavior score, diabetes knowledge,
BMI and Fasting Blood Glucose (FBG) between gender control-
ling for age; 2) To ﬁnd correlations between calories burnt by
exercise, compliance, eating behavior score, diabetes knowledge,
age, BMI and FBG; 3) To estimate Hierarchical Stepwise
Multiple Regression Analysis (MRA) model to predict FBG.
METHODS: A cross-sectional deductive survey by telephone
interviewing and accessing clinical data were employed to inves-
tigate relationship between health behavior factors namely—
calories burnt by exercise, compliance, eating behavior score,
demographic data and FBG of 200 type 2 diabetes patients at
Saraburi Hospital 2008, randomly generated by computer.
RESULTS: Total sample size of 200 (100%) diabetes patients,
mostly 138 (69.00%) were female, 62 (31.00%) were male with
average age 59.34  11.99 years, average BMI 26.79  2.50,
average calories burnt per week 2777.24  2420.89, average
compliance score 12.37  7.13, and average FBG 161.25 
54.10. Cronbach’s Alpha coefﬁcient of Sorofman’s Compliance
scale for constructs “right time” and “right amount” were
0.8157, and 0.8526 respectively and Auamnoy Eating Behavior
Scale was 0.7915. ANCOVA conﬁrmed that FBG, compliance,
A514 Abstracts
